Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.35 |
| ▸ | HTR3B | O95264 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.35 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540819 | 0.89 | ACKR3 (0.41) | ACKR3HTR2CALDH1A1KDM4EHTR3E | |
| SCHEMBL3541008 | 0.89 | TLR7 (0.45) | ACKR3HTR2CALDH1A1KDM4ECNR2 | |
| SCHEMBL3535648 | 0.88 | ACKR3 (0.47) | ACKR3HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL27730546 | 0.87 | ACKR3 (0.40) | ACKR3HTR2CALDH1A1KDM4EHTR3E | |
| SCHEMBL3537377 | 0.87 | ALDH1A1 (0.43) | ALDH1A1KDM4EPIM1 | |
| SCHEMBL3545134 | 0.86 | ACKR3 (0.46) | ACKR3HTR3EHTR3BCHRNA7HTR3A | |
| SCHEMBL3541605 | 0.86 | ACKR3 (0.37) | ACKR3HTR2CALDH1A1KDM4EHTR3E | |
| SCHEMBL3538996 | 0.86 | ACKR3 (0.37) | ACKR3HTR2CALDH1A1KDM4EHTR3E | |
| SCHEMBL4983913 | 0.85 | ACKR3 (0.45) | ACKR3ALDH1A1HTR3EHTR3BCHRNA7 | |
| SCHEMBL3538095 | 0.85 | HTR2C (0.37) | ACKR3HTR2CALDH1A1KDM4ECNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | claimed |
| CN-101370796-B | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE | 2012-10-10 | — | — | CN | disclosed |
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| CN-101370796-A | Thiazoles as 11 beta-HSD1 inhibitors | HOFFMANN LA ROCHE (CH) | 2009-02-18 | — | — | CN | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | NTMT1 2845/4885ACKR3 3834/4885HTR2C 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.